Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (CIAS) (e.g., impaired attention / vigilance, memory, executive function) in the United States or Europe. In fact, no drugs have demonstrated consistent efficacy in improving cognitive function among the sizeable schizophrenia population with cognitive deficit, and psychiatrists’ treatment options for these patients are limited. Given the paucity of therapeutic options and the long-term impact of cognitive deficits on patients’ quality of life and functioning, there is high unmet need and commercial opportunity for an efficacious and safe therapy to treat CIAS in this underserved schizophrenia segment.

QUESTIONS ANSWERED

  •  What is the relative importance of a therapy’s various attributes in psychiatrists’ prescribing decisions for CIAS (e.g., improvement in overall cognition, improvement in patient functioning, improvement in positive and negative symptoms)
  •  How do U.S. and European psychiatrists rate the performance of various current therapies on key treatment drivers and goals for CIAS?
  • What are the prevailing areas of unmet need and opportunity in the treatment of CIAS?
  • What trade-offs across key drug attributes and price are acceptable to psychiatrists for a hypothetical new drug for CIAS?

CONTENT HIGHLIGHTS

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in February 2020.

Key companies: Janssen, Otsuka Pharmaceuticals, Novartis, Allergan, Eisai, Teva, Pfizer.

Key drugs: Aripiprazole, rivastigmine, risperidone, memantine, donepezil, modafinil, sertraline.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)
    • Executive Summary
      • Unmet Need - CIAS - Executive Summary - April 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for CIAS and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Psychiatrists' Prescribing Decisions in CIAS
        • Importance of Efficacy Attributes to Prescribing Decisions in CIAS: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in CIAS: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in CIAS: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in CIAS: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in CIAS: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in CIAS: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in CIAS: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in CIAS: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in CIAS: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in CIAS: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for CIAS: United States
        • Overall Performance of Key Therapies for CIAS: Europe
        • Mean Overall Performance of Key Therapies for CIAS: United States and Europe
        • Relative Performance of Key Therapies for CIAS Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for CIAS Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for CIAS Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for CIAS Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for CIAS Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for CIAS Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for CIAS Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for CIAS Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in CIAS
        • Surveyed Psychiatrists' Satisfaction with the Performance of Key Therapies for CIAS on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Psychiatrists' Satisfaction with the Performance of Key Therapies for CIAS on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CIAS: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CIAS: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CIAS: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CIAS: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CIAS: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CIAS: Europe
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in CIAS: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in CIAS: Europe
        • Key Findings: Unmet Need in CIAS and Related Indications
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need in CIAS and Related Indications: United States
        • Surveyed Psychiatrists' Ascribed Level of Unmet Need in CIAS and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the CIAS Market and Emerging Therapy Insights
          • Opportunity: A Therapy Offering Improvement in Overall Cognition in Schizophrenia Patients
          • Opportunity: A Cognition-Enhancing Therapy Offering Improvement in Functioning in Patients with CIAS
          • Opportunity: An Efficacious Cognition-Enhancing Therapy That Improves the Residual Psychiatric Symptoms of Schizophrenia
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
        • Attribute Importance and Part-Worth Utilities
          • CIAS Target Product Profile: Attribute Importance
          • Improvement from Baseline in Overall MCCB Score vs. Placebo (Effect Size) at Week 24
          • Improvement from Baseline in UPSA Score vs. Placebo (Effect Size) at Week 24
          • Change from Baseline in PANSS Total Score vs. Placebo (Effect Size) at Week 24
          • % of Patients Who Experience Serious Adverse Events at Week 24
          • Long-Term Tolerability: % of Patients Ceasing Therapy Due to Adverse Events ≤ 1 Year
          • Delivery Profile
          • Price per Treated Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • CIAS Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • CIAS Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • CIAS Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Shefali Gulati, MBA Pharm

    Shefali Gulati, Associate analyst, is part of the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group.

    She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She comes with one year of experience working on multiple client projects revolving around opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds a MBA degree in Pharmaceutical Management from the National Institute of Pharmaceutical Education and Research (NIPER) in India and Bachelor’s in Pharmacy from DIPSAR.


    Related Reports

    Schizophrenia - Landscape & Forecast - Disease Landscape And Forecast G7

    The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are al...

    View Details

    Schizophrenia| Disease Landscape and Forecast | G7 | 2020

    The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also ava...

    View Details

    Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

    The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

    View Details

    Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

    Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

    View Details